INC Research to oversee Ph II trial for Cellectar Biosciences

By Melissa Fassbender

- Last updated on GMT

(Image: iStock/BernardaSv)
(Image: iStock/BernardaSv)
Cellectar Biosciences has announced INC Research as its contract research organization (CRO) for the company’s Phase II trial of CLR 131 in hematologic malignancies.

A $2m grant from the National Cancer Institute (NCI) will cover half the study cost, with the potential option to pursue another $3m for a pivotal Phase III trial of Cellectar’s lead radiotherapeutic compound.

According to the company, the results of the 80-patient, Phase II study will be used to design its pivotal trial of CLR 131 in multiple myeloma and other hematologic malignancies.

Jim Caruso, president and CEO of Cellectar described INC Research as the “ideal partner for this important trial​.”

The company expects to initiate the trial during the first quarter of 2017.

As many as 15 participating sites will be used in order to provide initial efficacy data in the second half of 2017.

Related topics Clinical Development Phase I-II

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars